Ellen Cahir-McFarland

We started out Q1 with cautious optimism and the numbers continue to show the confidence was warranted. Biopharma M&A activity more than doubled nationally during the year’s first three months, coinciding with a rebound in venture capital deals as well as a flurry of IPOs. These are all good signs that the drug development cycle is normalizing and should translate into additional funding being available at the seed and Series A stages. Certain to be on the minds of funders and startups attending #AlignSummit24 on Thursday! https://lnkd.in/erEiJm6S  

112

5 Comments

Glad to see more commitment from Bristol Myers Squibb Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries PRINCETON, NJ / ACCESSWIRE / May 22, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced ASPIRE (Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity), a 10-year strategy to advance access to our innovative treatments and help patients in low- and middle-income countries (LMICs) gain access to potentially life-saving medicines. This strategy supports the company's commitment to reach more than 200,000 patients in LMICs by 2033 with its innovative treatments. "Access to potentially life-saving innovative medicines is very limited in some parts of the world, leaving patients with few treatment options for serious diseases like cancer," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "Bristol Myers Squibb believes patients who can benefit from our medicines should have access to them. Our ASPIRE strategy is an important step toward accelerating and expanding patient access to these much-needed treatments." As part of ASPIRE, Bristol Myers Squibb (BMS) is developing tailored strategies to increase affordability and availability of its medicines in LMICs. Our work to help ensure patients who need our potentially life-saving medicines can access them begins by ensuring that 100 percent of our marketed products are supported by access plans. Today we have defined access pathways for every country in which our medicines may be available to patients. In low- and middle-income countries, to help improve the affordability of our medicines, we have introduced local brands of many of our innovative medicines to address affordability issues, expand access, and help reduce the time lag between the availability of our medicines in higher-income countries and lower-income countries. In 2023, BMS filed a total of 11 local brands of which five received regulatory approvals. BMS local brands are making an impact in countries like Thailand, which has the highest prevalence of beta thalassemia, by providing treatment options like Rojusna™ to help combat this widespread disease. BMS is also making its medicines available where we don't have a commercial presence through the Direct Import and the Direct-to-Institution pathways. Through the Direct Import pathway, BMS is providing access to 12 medicines in more than 80 LMICs, using tiered pricing commensurate with affordability. The Direct-to-Institution (DTI) pathway is a scalable and sustainable channel that provides safe, broad, timelier access to BMS' innovative medicines to multiple patients through collaboration with local institutions. The company's initial DTI efforts are in five LMICs in East Africa and Pakistan and West Africa https://lnkd.in/gR42JzGj

20

In a recent article for MedCity News, my colleague John Khoury and I explore the rapid growth of the #cellandgenetherapy industry, which despite economic challenges pulled in $11.7 billion in investments in 2023. We emphasize the critical role of informed #portfoliomanagement decisions in unlocking success, highlighting the importance of asset assessment and strategic alignment. By prioritizing R&D initiatives, effectively addressing societal needs, and embracing emerging technologies, companies can navigate market uncertainties and drive innovation in this competitive sector. For more insights into portfolio management strategies, read the full article on MedCity News.

39

Founded by senior Google and GRAIL executives, Betteromics are solving the unstructured data problems plaguing HC/LS and specifically leveraging Regulatory Grade GenAI for the creation of structured data (i.e. cancer staging, pharmacovigilance, etc.) from unstructured text. Dramatically faster / Traceable and verifiable / Easier, and more agile, than traditional methods

38

Alia Therapeutics is present at ASGCT Baltimore, the 27th Annual Meeting of American Society of Gene & Cell Therapy.  Meet Antonio Casini, Alia co-founder and CTO, on Wednesday 8th, presenting poster “ A novel mutation-independent CRISPR-based gene therapy to treat autosomal dominant retinitis pigmentosa”. https://lnkd.in/drdhej43 , POSTER SESSION B6 - Ophthalmic and Auditory Diseases 654   Alia Therapeutics has a vision to revolutionize medicine by curing genetic diseases at their roots. Our thesis: The diversity and complexity of human genetic diseases demands a customized approach and relying on a limited set of enzymes wouldn’t suffice. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomics sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which is required for therapeutic applications. Learn more at https://lnkd.in/dDVgwXVE #genetherapy, #geneediting, #asgct, #baltimore, #aliatherapeutics

34